Moreover, we demonstrated that Ponatinib has broader and superior anti-STAT3 inhibition compared to five inhibitors with anti-SRC or anti-JAK properties and that CRC cells displayed prolonged acquired resistance to Ponatinib compared to Dasatinib and Bosutinib. This evidence concerns the gene STAT3 and colorectal carcinoma.